We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+0.23%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.56B
AUM Growth
-$299M
Cap. Flow
+$625M
Cap. Flow %
8.26%
Top 10 Hldgs %
53.85%
Holding
87
New
11
Increased
24
Reduced
6
Closed
9

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$134M
2
CLYM
Climb Bio
CLYM
+$122M
3
ACLX
Arcellx
ACLX
+$87.2M
4
EVH icon
Evolent Health
EVH
+$71M
5
RNAM
Avidity Biosciences
RNAM
+$60.8M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$91.9M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$54.6M
3
CTKB icon
Cytek Biosciences
CTKB
+$45.7M
4
VXRT
Vaxart
VXRT
+$20M
5
EYPT icon
EyePoint Inc
EYPT
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.5B
$1.38B 18.23%
10,108,400
– –
PCVX icon
2
Vaxcyte
PCVX
$7.65B
$619M 8.19%
8,203,754
– –
JANX icon
3
Janux Therapeutics
JANX
$912M
$384M 5.08%
9,165,652
– –
LEGN icon
4
Legend Biotech
LEGN
$3.65B
$332M 4.4%
7,506,934
+645,837
+9% +$29.8M
RYTM icon
5
Rhythm Pharmaceuticals
RYTM
$7.31B
$250M 3.3%
6,084,412
+754,000
+14% +$30.1M
BIIB icon
6
Biogen
BIIB
$30.9B
$228M 3.01%
982,139
+241,412
+33% +$52.5M
CLYM
7
Climb Bio
CLYM
$693M
$223M 2.95%
31,419,267
+18,268,418
+139% +$122M
RXST icon
8
RxSight
RXST
$254M
$222M 2.94%
3,694,825
+252,000
+7% +$14.4M
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$221M 2.92%
5,400,408
+2,118,228
+65% +$60.8M
DYN icon
10
Dyne Therapeutics
DYN
$4.68B
$213M 2.82%
6,049,204
+1,094,425
+22% +$31.8M
GERN icon
11
Geron
GERN
$898M
$196M 2.59%
46,202,425
– –
PEPG icon
12
PepGen
PEPG
$118M
$171M 2.26%
10,689,545
– –
TYRA icon
13
Tyra Biosciences
TYRA
$1.85B
$167M 2.2%
10,416,609
– –
EVH icon
14
Evolent Health
EVH
$371M
$163M 2.15%
8,514,862
+2,778,730
+48% +$71M
EWTX icon
15
Edgewise Therapeutics
EWTX
$4.28B
$160M 2.12%
8,909,091
– –
NAMS icon
16
NewAmsterdam Pharma
NAMS
$3.26B
$155M 2.05%
8,064,000
+200,000
+3% +$4.01M
RXRX icon
17
Recursion Pharmaceuticals
RXRX
$1.58B
$115M 1.53%
+15,384,615
New +$134M
ETNB
18
DELISTED
89bio
ETNB
$114M 1.5%
14,175,398
+1,408,450
+11% +$12.6M
VRNA
19
DELISTED
Verona Pharma
VRNA
$110M 1.46%
7,632,646
+1,314,656
+21% +$19.2M
DAWN
20
DELISTED
Day One Biopharmaceuticals
DAWN
$108M 1.43%
7,871,721
+61,869
+0.8% +$905K
FDMT icon
21
4D Molecular Therapeutics
FDMT
$502M
$107M 1.42%
5,098,211
+46,700
+0.9% +$1.17M
SPRY icon
22
ARS Pharmaceuticals
SPRY
$579M
$92.4M 1.22%
10,860,977
– –
WVE icon
23
Wave Life Sciences
WVE
$1.12B
$90.8M 1.2%
18,202,009
– –
LBPH
24
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$88.9M 1.18%
3,289,119
– –
ACLX
25
DELISTED
Arcellx
ACLX
$88.5M 1.17%
+1,604,014
New +$87.2M
1
2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, RA Capital Management held 87 positions worth $7.56B, down 3.8% from $7.86B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

RA Capital Management deployed $625M of net new capital in Q2 2024, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was iTeos Therapeutics, an estimated $12.9M trimmed.

  • RA Capital Management's largest Q2 2024 buy was Recursion Pharmaceuticals: 15,384,615 shares worth $115M.
  • RA Capital Management added most to Climb Bio in Q2 2024, an estimated $122M increase.
  • RA Capital Management's biggest Q2 2024 reduction was iTeos Therapeutics, cutting an estimated $12.9M.
  • RA Capital Management fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $91.9M.
  • RA Capital Management's ten largest holdings make up 54% of its $7.56B portfolio in Q2 2024.
  • RA Capital Management opened 11 new positions and closed 9 in Q2 2024.
  • RA Capital Management's portfolio value fell 3.8% quarter-over-quarter to $7.56B.

Based on RA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.